Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Phase 2 N=283 Randomized Triple-blind Treatment

Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy

Vaginal Atrophy

Bottom Line

View on ClinicalTrials.gov: NCT02967510 ↗
Enrolled (actual)
283
Serious AEs
1.1%
Results posted
Sep 2019
Primary outcome: Primary: Change From Baseline to Week 12 in the Severity of Vaginal Dryness — 15; 13; 13; 9 Participants — p==0.304

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Estriol (Drug); Placebo (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
Female
Sponsor
ITF Research Pharma, S.L.U.
Primary completion
May 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline to Week 12 in the Severity of Vaginal Dryness		 15; 13; 13; 9; 23; 33 =0.304
PRIMARY
Change From Baseline to Week 12 in Vaginal pH		 -1.03; -1.04; -0.95; -0.29 <0.001 sig
PRIMARY
Change From Baseline to Week 12 in the Proportion of Superficial Cells of the Vaginal Epithelium.		 0.24; 0.17; 0.19; 0.02 <0.001 sig
PRIMARY
Change From Baseline to Week 12 in the Proportion of Parabasal Cells of the Vaginal Epithelium.		 -0.54; -0.51; -0.47; -0.04 <0.001 sig
SECONDARY
Change From Baseline to Week 12 in the Severity of Dyspareunia		 7; 5; 4; 3; 9; 7 =0.47
SECONDARY
Change From Baseline to Week 12 in the Severity of Pruritus or Itching		 2; 5; 4; 4; 16; 14 =0.329
SECONDARY
Change From Baseline to Week 12 in the Severity of Burning		 5; 4; 7; 4; 22; 21 =0.122
SECONDARY
Change From Baseline to Week 12 in the Severity of Dysuria		 0; 1; 1; 1; 8; 8 =0.393
SECONDARY
Change From Baseline to Week 12 in the Global Symptom Score 1		 -4.30; -4.78; -4.51; -4.54 =0.65
SECONDARY
Change From Baseline to Week 12 in the Global Symptom Score 2		 -3.83; -3.78; -3.74; -3.27 =0.043 sig
SECONDARY
Change From Baseline to Week 12 in the Severity of Pallor.		 3; 5; 1; 1; 17; 16 =0.012 sig
SECONDARY
Change From Baseline to Week 12 in the Severity of Friability		 2; 2; 2; 3; 19; 21 =0.438
SECONDARY
Change From Baseline to Week 12 in the Severity of Thinning or Flattening of Folds		 4; 1; 1; 1; 18; 18 =0.022 sig
SECONDARY
Change From Baseline to Week 12 in the Severity of Petechiae		 2; 1; 0; 2; 10; 5 =0.002 sig
SECONDARY
Change From Baseline to Week 12 in the Severity of Dry Mucosa		 8; 13; 14; 9; 39; 29 =0.022 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Vaginal Dryness		 6; 8; 8; 3; 23; 13 =0.176
SECONDARY
Change From Baseline to Week 3 in the Severity of Dyspareunia		 1; 3; 4; 2; 7; 4 =0.106
SECONDARY
Change From Baseline to Week 3 in the Severity of Pruritus or Itching		 1; 4; 2; 1; 10; 10 =0.026 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Burning		 3; 2; 4; 0; 11; 17 =0.36
SECONDARY
Change From Baseline to Week 3 in the Severity of Dysuria		 0; 0; 1; 0; 5; 8 =0.47
SECONDARY
Change From Baseline to Week 3 in the Global Symptom Score 1		 -2.99; -2.86; -4.37; -3.73 =0.85
SECONDARY
Change From Baseline to Week 3 in the Global Symptom Score 2		 -2.76; -2.82; -3.20; -2.60 =0.323
SECONDARY
Change From Baseline to Week 3 in the Severity of Pallor		 3; 2; 1; 0; 14; 14 =0.009 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Friability		 2; 2; 1; 0; 14; 11 =0.04 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Thinning or Flattening of Folds		 1; 1; 0; 0; 12; 9 <0.001 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Presence of Petechiae		 2; 0; 0; 0; 8; 6 <0.001 sig
SECONDARY
Change From Baseline to Week 3 in the Severity of Dry Mucosa		 4; 8; 6; 3; 29; 20 =0.008 sig
SECONDARY
Change From Baseline to Week 3 in Vaginal pH		 -1.03; -0.97; -0.88; -0.22 <0.001 sig
SECONDARY
Change From Baseline to Week 3 in the Proportion of Superficial Cells of the Vaginal Epithelium		 0.48; 0.43; 0.38; 0.04 <0.001 sig
SECONDARY
Change From Baseline to Week 3 in the Proportion of Parabasal Cells of the Vaginal Epithelium		 -0.55; -0.57; -0.48; -0.08 <0.001 sig

Summary

A Phase 2, Dose-ranging, 12-week Randomized, Double-blind, Placebo controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005% Estriol Vaginal Gel, 0.002% Estriol Vaginal Gel, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women with Vulvovaginal Atrophy. Vulvovaginal atrophy is a natural consequence of the progressive estrogen deficiency that occurs in menopause. Epidemiological data have indicated that about 50% of otherwise healthy women over 60 years of age experience symptoms related to urogenital atrophy such as vaginal dryness, dyspareunia, burning, itching, as well as urinary complaints or infections of the lower urinary tract. As these alterations frequently affect the quality of life of postmenopausal women, it is important for doctors to detect their presence and offer treatment options. Estrogen therapy is the most effective treatment of moderate to severe symptoms of vulvar and vaginal atrophy. One advantage of local treatment with estrogen is avoidance of first-pass liver metabolism, making it possible to use lower doses of estrogen compared with oral therapy; the local route also minimize systemic adverse effects. The search for therapeutic alternatives which may present improvements in relation to the current products has been encouraged.

Eligibility Criteria

Inclusion Criteria

  • Capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with the protocol procedures and assessments
  • Age >40 and 40 IU/L, or ≥6 weeks since bilateral oophorectomy with or without hysterectomy)
  • BMI ≤36 kg/m2
  • Vaginal Maturation Index ≤ 5% superficial cells on a vaginal smear
  • Vaginal pH >5
  • Moderate to severe vaginal dryness currently reported as the most bothersome symptom of vaginal atrophy.
  • Documented negative mammogram within 9 months prior to randomization, with normal breast examination at screening.
  • Negative Papanicolau test at screening (in women with cervix).

Exclusion Criteria

  • Subjects with contraindications for hormone therapy with estrogens such as those diagnosed or history of: malignant and premalignant lesions of the breast and/or endometrium, malignancy of the colon, malignant melanoma, hepatic tumor, venous thromboembolic conditions (including deep vein thrombosis or pulmonary embolism), arterial thromboembolic conditions (including angina pectoris, myocardial infarction, or cerebrovascular accident), coagulopathies, vaginal bleeding of unknown etiology, acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal, or porphyria.
  • Subjects who have abnormal laboratory values at screening that the investigator considers clinically relevant for the purposes of the study.
  • Subjects with any medical-surgical pathology which is not controlled at the time of inclusion in the study
  • Subjects with any acute or chronic condition whose management or progression may interfere with the subject´s participation in the study.
  • Subject with uncontrolled hypertension (>140 mmHg systolic blood pressure and/or ≥90 mmHg diastolic blood pressure).
  • Subjects with Grade II or higher utero-vaginal prolapse.
  • Subjects with uterine polyps.
  • Subjects with symptomatic and/or large uterine fibroids (>3 cm) and/or palpable fibroids at gynecological examination.
  • Subjects who have had urogenital surgery within 3 months of baseline visit.
  • Subjects with signs and symptoms suggestive of infection of the genital or urinary tract requiring treatment at the start of the study.
  • In women who have a uterus, evidence of hyperplasia, cancer or other endometrial pathology in endometrial biopsy.
  • Subjects who have received the following treatments within the specified time periods prior to screening procedures: any type of non-hormonal vulvovaginal treatment in the 7 days (including cosmetics expected to have an impact on vaginal pH such as special feminine wash gels); phytoestrogens by any route within 1 month; vaginal hormone therapy within 1 month; hormone therapy (estrogen alone, progestin alone or estrogen/progestin combination) by oral, intrauterine or transdermal route within 2 months; progestational implants, estrogen, or estrogen/progestational injectable within 3 months; estrogen pellet therapy or progestin injectable drug therapy within 6 months; percutaneous estrogen lotions or gels within 1 month; testosterone or testosterone derivatives, DHEA, tibolone, or SERMs by any route within 2 months;
  • Subjects receiving antiepileptic drugs (barbiturates, hydantoins, carbamazepine), certain antibiotics and other antiinfective medicinal products; phenylbutazone; preparations based on medicinal plants that contain St. John's Wort.
  • Subjects who are allergic to any of the components of the medication under study.
  • Subjects who are currently participating or have participated in the experimental evaluation of any product within 8 weeks of the start of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02967510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search